Main Results of 2025 Annual and Extraordinary General Meeting
The 2025 Annual and Extraordinary General Meeting (the '2025 AGM') of Alvotech (the 'Company') was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg.
All of the draft resolutions on the 2025 AGM agenda were approved. Notarized meeting minutes and voting results will be published on the Company's special web portal for the 2025 Annual General Meeting at:
Advertisement
https://investors.alvotech.com/corporate-governance/annual-general-meeting-2025
Alvotech Investor Relations
Benedikt Stefansson
[email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
an hour ago
- Hamilton Spectator
Optiva Inc. Announces Results of Annual Meeting
TORONTO, June 25, 2025 (GLOBE NEWSWIRE) — Optiva Inc. ('Optiva' or the 'Company') (TSX:OPT), a leader in powering the telecom industry with cloud-native billing, charging and revenue management software on private and public clouds, today announced that Patrick DiPietro, Lee Matheson, Simon Parmar, Robert Stabile, Barry Symons, and Birgit Troy were elected to the Company's board of directors (the 'Board') at the Company's annual meeting of holders of common shares held earlier today (the 'Meeting'). In addition, a resolution was carried at the Meeting to re-appoint KPMG LLP as the auditor of the Company and to authorize the Board to fix the auditor's remuneration. Detailed results of the votes are as follows: 1. Election of Directors 2. Appointment and Remuneration of Auditor Appointment of KPMG LLP as the auditor of the Company and authorizing the Company's board of directors to fix the remuneration of the auditor. About Optiva Inc. Optiva Inc. is a leading provider of mission-critical, cloud-native, agentic AI-powered revenue management software for the telecommunications industry. Its products are delivered globally on the private and public cloud. The Company's solutions help service providers maximize digital, 5G, IoT and emerging market opportunities to achieve business success. Established in 1999, Optiva Inc. is listed on the Toronto Stock Exchange (TSX:OPT). For more information, visit . For additional information, please contact:
Business Wire
4 hours ago
- Business Wire
Sizzling Platter Prices Offering of $500 Million Senior Secured Notes to Finance Acquisition by Bain Capital Private Equity
SALT LAKE CITY--(BUSINESS WIRE)--Sizzling Platter, one of the largest U.S. restaurant franchisee platforms, today announced that affiliates of Bain Capital Private Equity have priced $500 million in aggregate principal amount of 9.500% senior secured notes due 2032 (the 'notes'), to fund the acquisition of Sizzling Platter's parent (the 'Company') by Bain Capital Private Equity. The affiliates, BCPE Flavor Debt Merger Sub, LLC ('Merger Sub') and BCPE Flavor Issuer, Inc. (the 'Co-Issuer') intend to use the net proceeds from the notes offering, together with borrowings under new senior secured credit facilities and equity contributions, to fund the acquisition, repay Sizzling Platter's existing indebtedness and pay related fees and expenses, with the remainder to be used for general corporate purposes. This press release does not constitute a notice of repayment of any outstanding indebtedness of Sizzling Platter. The notes will mature on July 1, 2032, unless earlier repurchased or redeemed in accordance with their terms. The notes offering is expected to close on July 2, 2025, subject to customary closing conditions. Upon consummation of the acquisition, the notes will be guaranteed jointly and severally on a senior secured basis by each existing and future wholly owned subsidiary of the Company (other than the Co-Issuer) that guarantees the Company's obligations under the new senior secured credit facilities, subject to certain exclusions. The notes and the related guarantees were offered to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the 'Securities Act'), and to non-U.S. persons in offshore transactions pursuant to Regulation S under the Securities Act. The notes and related guarantees have not been and will not be registered under the Securities Act or any state or other jurisdiction's securities laws. Accordingly, the notes may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the Securities Act and any applicable state or other jurisdiction's securities laws. This press release is neither an offer to sell nor a solicitation of an offer to buy any securities and shall not constitute an offer to sell or a solicitation of an offer to buy, or a sale of any securities in any jurisdiction in which such offer, solicitation or sale is unlawful. Forward-Looking Statements This press release contains statements that are forward-looking statements within the meaning of the federal securities laws and are subject to various risks, uncertainties and assumptions. All statements that are not historical in nature, and which may be identified by the use of words such as 'expects,' 'plans,' 'seeks,' 'anticipates,' 'strategy,' 'believes,' 'intends,' 'may,' 'outlook,' 'forecasts,' 'goal,' 'estimates' and other similar expressions or future or conditional verbs such as 'will,' 'should,' 'would' and 'could' and similar expressions (or the negative of such expressions), are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the proposed merger and the expected closing of the offering. Forward-looking statements are made based on our current expectations and beliefs concerning future events and, therefore, involve a number of assumptions, risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those indicated by such forward-looking statements. The Company undertakes no obligation to update our forward-looking statements to reflect events and circumstances after the date on which the statements were made or to reflect the occurrence of unanticipated events.
Business Wire
6 hours ago
- Business Wire
HIMS CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit on Behalf of Hims & Hers Health, Inc. Investors
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP ('GPM'), announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Sookdeo v. Hims & Hers Health, Inc., et al., Case No. 3:25-cv-05315, on behalf of persons and entities that purchased or otherwise acquired Hims & Hers Health, Inc. ('Hims' or the 'Company') (NYSE: HIMS) securities between April 29, 2025 and June 22, 2025, inclusive (the 'Class Period'). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the 'Exchange Act'). Investors are hereby notified that they have 60 days from the date of this notice to move the Court to serve as lead plaintiff in this action. IF YOU SUFFERED A LOSS ON YOUR HIMS INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? On April 29, 2025, Hims announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of 'a bundled offering of Novo Nordisk's FDA-approved Wegovy on the Hims & Hers platform.' On June 23, 2025, before the market opened, Novo Nordisk issued a press release announcing that it was terminating its partnership with Hims, 'based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.' The press release stated that Hims 'has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization.'' The press release further stated '[b]ased on Novo Nordisk's investigation, the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China' which 'FDA has never authorized or approved' and which may contain 'unsafe and illicit foreign ingredients.' On this news, the Company's share price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025, on unusually heavy trading volume. What Is the Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Hims was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk;' (2) that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. If you purchased or otherwise acquired Hims securities during the Class Period, you may move the Court no later than 60 days from the date of this notice to ask the Court to appoint you as lead plaintiff. Contact Us to Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq. Glancy Prongay & Murray LLP 1925 Century Park East, Suite 2100 Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
